

MINUTES
UTAH ADVISORY PHARMACY COMPOUNDING EDUCATION COMMITTEE
March 20, 2025 | 9:00 A.M.
ROOM 474, 4th Floor
160 E 300 S Salt Lake City UT
Hybrid Meeting- In Person and Electronic

CONVENED: 9:01 A.M.

ADJOURNED: 9:48 A.M.

DOPL STAFF PRESENT ELECTRONICALLY:

Bureau Manager: Jim Garfield
Board Secretary: Tina Marshall

Pharmacy Specialist: Maddy Holt
Investigator: Travis Drebing

COMMITTEE MEMBERS PRESENT ELECTRONICALLY:

Chair: Chris Cox, Pharm.D.

Robb Dengg, Pharm.D.

Vice Chair: Hali O'Malley, Pharm.D.

Richard Cox, Pharm.D.

Casey Sayre, Pharm.D.

COMMITTEE MEMBERS NOT PRESENT:

Adam Taintor, MD

Jeremy Olsen, Pharm.D.

GUESTS ATTENDED ELECTRONICALLY:

Note: Others may have attended, but were not identified.

ADMINISTRATIVE BUSINESS:

CALL MEETING TO ORDER

Dr. Cox called the meeting to order at 9:01 A.M.

Read and Approve December 12, 2024 Minutes (Audio 00:02:48)

Dr. Dengg made a motion approving the minutes as written.

Dr. Richard Cox seconded the motion.

The committee motion passed unanimously.

DISCUSSION ITEMS:

Kits (Audio 00:03:49)

Dr. Chris Cox explained the discussion the Committee had at the last committee meeting regarding prepackaged kits.

Dr. O'Malley explained that the website for the kits states that they are intended for compounding pharmacists and compounding pharmacies only.

Dr. Chris Cox agreed with Dr. O'Malley explanation of what is found on the website for the kits.

Dr. Richard Cox asked if it would still be considered compounding if the pharmacy was following the package insert.

Dr. Dengg explained that the kits are not FDA approved and because of this they do not have package inserts.

The Committee agreed that with the information provided that the kits are for compounding pharmacists and compounding pharmacies only.

FDA Tirzepatide and Semaglutide Shortage (Audio 00:21:35)

Dr. Chris Cox gave a background of the removal of Tirzepatide and Semaglutide from the FDA shortage list and the lawsuits that followed. The FDA issued an update on March 10, 2025 on their website.

Dr. Chris Cox discussed the FDA update that pharmacies are no longer allowed to compound essential copies of Tirzepatide. The FDA provided dates on which compounding essential copies of Semaglutide can be done.

Mr. Garfield and the Committee discussed ways that the information can be provided to the compounding pharmacists in the State.

Newsletter (Audio 00:39:41)

Dr. Chris Cox volunteered to write an article for the next NABP newsletter on the Tirzepatide and Semaglutide shortages and the update from the FDA.

NEXT SCHEDULED MEETING: Thursday, June 19, 2025.

ADJOURNED: Meeting adjourned at 9:48 A.M.

Note: These minutes are not intended to be a verbatim transcript but are intended to record the significant features of the business conducted in this meeting. Discussed items are not necessarily shown in the chronological order they occurred.

(ss) _____
Chairperson _____
Advisory Pharmacy Compounding Education
Committee _____
Date _____

(ss) _____
Bureau Manager _____
Date _____